Lyra Therapeutics Overview
- Year Founded
-
2005

- Status
-
Public
- Employees
-
87

- Stock Symbol
-
LYRA

- Share Price
-
$0.21
- (As of Friday Closing)
Lyra Therapeutics General Information
Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Contact Information
Website
lyratherapeutics.comCorporate Office
- 480 Arsenal Way
- Watertown, MA 02472
- United States
Corporate Office
- 480 Arsenal Way
- Watertown, MA 02472
- United States
Lyra Therapeutics Timeline
Lyra Therapeutics Stock Performance
As of 14-Feb-2025, Lyra Therapeutics’s stock price is $0.21. Its current market cap is $13.6M with 65.5M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.21 | $0.21 | $0.16 - $6.79 | $13.6M | 65.5M | 1.69M | -$1.49 |
Lyra Therapeutics Financials Summary
As of 30-Sep-2024, Lyra Therapeutics has a trailing 12-month revenue of $1.47M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | (13,928) | 179,171 | (8,964) | 277 |
Revenue | 1,471 | 1,558 | 1,363 | 285 |
EBITDA | (101,012) | (66,842) | (55,239) | (42,614) |
Net Income | (97,612) | (62,680) | (55,278) | (43,513) |
Total Assets | 78,756 | 142,600 | 109,968 | 54,867 |
Total Debt | 35,324 | 26,881 | 4,177 | 1,453 |
Lyra Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Lyra Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Lyra Therapeutics Comparisons
Industry
Financing
Details
Lyra Therapeutics Competitors (31)
One of Lyra Therapeutics’s 31 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
VeriNOS Pharmaceuticals | Private Equity-Backed | Wuerzburg, Germany | ||||
Nextera | Venture Capital-Backed | Oslo, Norway | ||||
Cyteir Therapeutics | Formerly VC-backed | Lexington, MA | ||||
MEI Pharma | Corporation | San Diego, CA |
Lyra Therapeutics Patents
Lyra Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2022234748-A1 | Implantable corticosteroid matrix for sinus condition | Pending | 08-Mar-2021 | ||
GB-202313054-D0 | Implantable corticosteroid matrix for sinus condition | Pending | 08-Mar-2021 | ||
GB-2618726-A | Implantable corticosteroid matrix for sinus condition | Pending | 08-Mar-2021 | ||
CA-3210984-A1 | Implantable corticosteroid matrix for sinus condition | Pending | 08-Mar-2021 | ||
US-20240041590-A1 | Implantable corticosteroid matrix for sinus condition | Pending | 08-Mar-2021 | A61F2/186 |
Lyra Therapeutics Signals
Lyra Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Lyra Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Pharmaceuticals
Subindustry
Rank
Percentile

Lyra Therapeutics FAQs
-
When was Lyra Therapeutics founded?
Lyra Therapeutics was founded in 2005.
-
Where is Lyra Therapeutics headquartered?
Lyra Therapeutics is headquartered in Watertown, MA.
-
What is the size of Lyra Therapeutics?
Lyra Therapeutics has 87 total employees.
-
What industry is Lyra Therapeutics in?
Lyra Therapeutics’s primary industry is Drug Discovery.
-
Is Lyra Therapeutics a private or public company?
Lyra Therapeutics is a Public company.
-
What is Lyra Therapeutics’s stock symbol?
The ticker symbol for Lyra Therapeutics is LYRA.
-
What is the current stock price of Lyra Therapeutics?
As of 14-Feb-2025 the stock price of Lyra Therapeutics is $0.21.
-
What is the current market cap of Lyra Therapeutics?
The current market capitalization of Lyra Therapeutics is $13.6M.
-
What is Lyra Therapeutics’s current revenue?
The trailing twelve month revenue for Lyra Therapeutics is $1.47M.
-
Who are Lyra Therapeutics’s competitors?
NexImmune, VeriNOS Pharmaceuticals, Nextera, Cyteir Therapeutics, and MEI Pharma are some of the 31 competitors of Lyra Therapeutics.
-
What is Lyra Therapeutics’s annual earnings per share (EPS)?
Lyra Therapeutics’s EPS for 12 months was -$1.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »